Market open
INmune Bio/$INMB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About INmune Bio
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Ticker
$INMB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
14
Website
INmune Bio Metrics
BasicAdvanced
$103M
Market cap
-
P/E ratio
-$2.19
EPS
1.85
Beta
-
Dividend rate
Price and volume
Market cap
$103M
Beta
1.85
52-week high
$14.74
52-week low
$4.32
Average daily volume
217K
Financial strength
Current ratio
2.594
Quick ratio
2.53
Long term debt to equity
0.734
Total debt to equity
7.532
Interest coverage (TTM)
-23.93%
Management effectiveness
Return on assets (TTM)
-44.97%
Return on equity (TTM)
-98.97%
Valuation
Price to revenue (TTM)
2,091.768
Price to book
2.67
Price to tangible book (TTM)
4.65
Price to free cash flow (TTM)
-3.411
Growth
Revenue change (TTM)
-81.25%
Earnings per share change (TTM)
43.07%
3-year revenue growth (CAGR)
13.14%
3-year earnings per share growth (CAGR)
11.22%
What the Analysts think about INmune Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for INmune Bio stock.
INmune Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
INmune Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
INmune Bio News
AllArticlesVideos
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower
GlobeNewsWire·4 weeks ago
INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for INmune Bio stock?
INmune Bio (INMB) has a market cap of $103M as of December 30, 2024.
What is the P/E ratio for INmune Bio stock?
The price to earnings (P/E) ratio for INmune Bio (INMB) stock is 0 as of December 30, 2024.
Does INmune Bio stock pay dividends?
No, INmune Bio (INMB) stock does not pay dividends to its shareholders as of December 30, 2024.
When is the next INmune Bio dividend payment date?
INmune Bio (INMB) stock does not pay dividends to its shareholders.
What is the beta indicator for INmune Bio?
INmune Bio (INMB) has a beta rating of 1.85. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.